CA
NZ
UK
AU
IND
US
…
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Scopus Biopharma Inc is an OTC-listed biotechnology company; public filings are limited and its product pipeline and commercialization status are not fully detailed. Long-term growth may depend on clinical and regulatory progress, strategic partnerships and access to development capital, which could support value creation if programs advance.
Key risks include limited public disclosure and low trading liquidity, plus typical biotech exposures to clinical or regulatory failure, financing requirements and potential equity dilution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -11.71M | -26.95M | -10.86M | -2.69M | -0.69M |
| Minority interest | 0.11M | - | - | - | - |
| Net income | -11.61M | -25.50M | -11.57M | -2.69M | -0.69M |
| Selling general administrative | 9.03M | 12.61M | 2.73M | 2.23M | 0.41M |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Ebit | -11.71M | -27.63M | -10.16M | -2.69M | -0.69M |
| Ebitda | -11.71M | -27.63M | -10.15M | -2.69M | -0.69M |
| Depreciation and amortization | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Operating income | -11.71M | -27.63M | -10.16M | -2.69M | -0.69M |
| Other operating expenses | 11.71M | 27.63M | 10.16M | 2.69M | 0.69M |
| Interest expense | 0.00M | 0.77M | 0.71M | 0.00M | 0.00M |
| Net interest income | 0.00M | -0.77M | -0.71M | - | - |
| Income tax expense | -0.11M | -1.46M | 0.71M | 0.00M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 11.71M | 27.63M | 10.16M | 2.69M | 0.69M |
| Total other income expense net | - | 0.68M | -0.71M | -2.69M | -0.69M |
| Net income from continuing ops | -11.71M | -26.95M | -10.86M | -2.69M | -0.69M |
| Net income applicable to common shares | -11.61M | -26.95M | -10.86M | -2.69M | -0.69M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 0.39M | 8.19M | 1.97M | 0.77M | 0.13M |
| Other current assets | 0.27M | 0.24M | 0.14M | 0.00M | 0.10M |
| Total liab | 7.45M | 4.17M | 3.81M | 0.85M | 0.14M |
| Total stockholder equity | -6.56M | 4.02M | -1.83M | -0.08M | -0.01M |
| Other current liab | 7.45M | 4.17M | 1.52M | 0.85M | 0.14M |
| Common stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -53.06M | -41.46M | -14.50M | -3.64M | -0.95M |
| Cash | 0.12M | 7.94M | 1.83M | 0.04M | 0.00M |
| Total current liabilities | 7.45M | 4.17M | 3.81M | 0.85M | 0.14M |
| Net debt | -0.12M | -7.94M | 0.45M | -0.04M | -0.00M |
| Short term debt | - | - | 2.28M | - | - |
| Short long term debt | - | - | 2.28M | - | - |
| Short long term debt total | - | - | 2.28M | - | - |
| Other stockholder equity | 46.48M | 45.54M | 12.72M | 3.58M | 0.94M |
| Property plant equipment | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total current assets | 0.39M | 8.18M | 1.97M | 0.77M | 0.13M |
| Net tangible assets | -6.56M | 4.02M | -1.83M | -0.08M | -0.01M |
| Net receivables | - | - | - | 0.00M | 0.03M |
| Inventory | - | - | - | 0.73M | - |
| Accounts payable | 0.18M | 0.12M | 1.52M | 0.16M | - |
| Accumulated other comprehensive income | -0.00M | -0.09M | -0.07M | -0.03M | -0.01M |
| Common stock total equity | - | - | 0.01M | 0.01M | 0.01M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.00M | -0.00M | 0.00M | -0.00M | - |
| Change to liabilities | 3.01M | 2.94M | 1.18M | 0.32M | 0.00M |
| Total cashflows from investing activities | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M |
| Net borrowings | - | -0.10M | 2.19M | 2.19M | 2.19M |
| Total cash from financing activities | 0.24M | 17.56M | 4.35M | 2.18M | 0.60M |
| Change to operating activities | 0.23M | -0.10M | -0.04M | 0.04M | -0.13M |
| Net income | -11.71M | -26.95M | -10.86M | -2.69M | -0.69M |
| Change in cash | -7.82M | 6.11M | 1.80M | 0.04M | -0.16M |
| Begin period cash flow | 7.94M | 1.83M | 0.04M | 0.00M | 0.16M |
| End period cash flow | 0.12M | 7.94M | 1.83M | 0.04M | 0.00M |
| Total cash from operating activities | -8.13M | -11.42M | -2.53M | -2.12M | -0.75M |
| Issuance of capital stock | 0.00M | 20.10M | 3.27M | 1.78M | 0.54M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other cashflows from financing activities | 0.24M | -2.44M | 1.08M | 0.41M | 0.06M |
| Change to netincome | 0.25M | 12.69M | 6.64M | 0.21M | 0.07M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 3.23M | 2.84M | 1.15M | 0.36M | -0.13M |
| Stock based compensation | 0.35M | 0.67M | 0.27M | 0.12M | 0.07M |
| Other non cash items | - | 12.02M | 6.92M | 0.09M | - |
| Free cash flow | -8.13M | -11.43M | -2.53M | -2.12M | -0.75M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| SCPS Scopus Biopharma Inc |
- -% |
0.00 | - | - | - | 2.42 | 0.12 |
| NVO Novo Nordisk A/S |
0.41 1.00% |
41.10 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
43.35 4.73% |
959.41 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.
420 Lexington Avenue, New York, NY, United States, 10170
212 479 2513
13
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert J. Gibson | Vice Chairman, Sec. & Treasurer | NA |
| Mr. Ira Scott Greenspan | Sr. Advisor & Director | 1959 |
| Mr. David Silberg | Sr. Advisor | 1949 |
| Dr. Alan D. Horsager Ph.D. | Pres?of?Immuno-Oncology and Pres & CEO of Duet BioTherapeutics | 1973 |
| Mr. Ira Scott Greenspan | Senior Advisor & Director | 1959 |
| Mr. Robert J. Gibson | Vice Chairman, Secretary & Treasurer | NA |
| Dr. Alan D. Horsager Ph.D. | President?of?Immuno-Oncology and President & CEO of Duet BioTherapeutics | 1974 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.29%
Communication Services
+0.51%
Consumer Cyclical
-0.08%
Consumer Defensive
-0.14%
Energy
+1.08%
Financial Services
+0.14%
Financials
-0.06%
Healthcare
+0.51%
Industrials
+0.47%
Real Estate
-0.23%
Technology
+2.03%
Utilities
-0.13%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...